Skip to main content
. Author manuscript; available in PMC: 2012 Apr 4.
Published in final edited form as: Mol Cancer Ther. 2010 Sep 3;9(11):3065–3073. doi: 10.1158/1535-7163.MCT-10-0623

Figure 4. Analysis of ΔFRET ratios by FACS.

Figure 4

Flow cytometric analysis indicating the FRET YFP/CFP ratio in populations of cells with Picchu-CAAX alone (black), with Picchu-CAAX and Bcr-Abl (blue), and with Picchu-CAAX + Bcr-Abl followed by 5 µM Imatinib treatment (red). In panel B, a soluble form of Picchu was used while in panel A, a membrane targeted CAAX-fused version of Picchu was used. Note that both Picchu isoforms are highly labile to Imatinib.